Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

• Dirk Schadendorf,
• Caroline Robert,
• Antoni Ribas,
• Reinhard Dummer,
• Paolo A Ascierto,
• Georgina V Long,
• Daniel Gusenleitner,
• Eduard Gasal,
• Hussein A Tawbi,
• Alexander Savchenko,
• Jan C Brase,
• Paul D Nathan,
• James Garrett,
• Keith T Flaherty,
• Güllü Görgün

Affiliations

Dirk Schadendorf

Department of Dermatology, University Hospital of Essen, Essen, Germany

Caroline Robert

Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France

Antoni Ribas

Department of Medicine, University of California Los Angeles, Los Angeles, California, USA

Reinhard Dummer

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

Paolo A Ascierto

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

Georgina V Long

Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia

Daniel Gusenleitner

Aff2 0000 0001 2106 9910grid.65499.37Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA

Eduard Gasal

Global Drug Development, Oncology, Novartis, East Hanover, New Jersey, USA

Hussein A Tawbi

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Alexander Savchenko

3Novartis Pharmaceuticals, Cambridge, MA, USA

Jan C Brase

Sividon Diagnostics, Cologne, Germany

Paul D Nathan

4Division of Cancer Services, Mt Vernon Cancer Centre, Northwood, UK 

James Garrett

Head of current affairs

Keith T Flaherty

Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA

Güllü Görgün

Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA